{"title":"伊朗8个三级医疗中心601例毛霉菌病患者的10年观察","authors":"Hamid Badali, Bahar Mohamadi, Shahram Mahmoudi, Maryam Nasirian, Siavash Amiri, Shirin Irani, Zeynab Yassin, Narges Vaseghi, Ilad Alavi Darazam, Mohammadreza Salehi, Maryam Roham, Sara Abolghasemi, Farshad Divsalar, Mehrdad Hasibi, Atousa Hakamifard, Maryamosadat Hashemi Bafghi, Simin Saberi, Afsane Vaezi","doi":"10.1007/s11046-025-00995-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mucormycosis is a rare, destructive, and life-threatening angio-invasive fungal infection caused by fungi of the order Mucorales. This study highlights the urgent need for more extensive research in this regard. We aimed to assess the epidemiology of mucormycosis at eight tertiary-care centers in Iran over ten years (2010-2020).</p><p><strong>Methods: </strong>In the current retrospective study, eligible patients were included based on positive histopathology and direct microscopy by potassium hydroxide (KOH). Data collection started on July 26, 2021, and included data from February 15, 2010, to May 16, 2020.</p><p><strong>Results: </strong>Diabetes mellitus was the chief underlying condition related to mucormycosis. Rhino-cerebral, rhino-sino, and rhino-sino-orbital infections were observed in 53.2%, 23.8%, and 23% of these patients. Among the 108 cases with a culture, Rhizopus species were the most prevalent, followed by Mucor species. Over half of the patients received surgery/antifungal treatment, with an overall antifungal prescribing rate of 66.7% of patients within the study period. However, surgery was associated with better clinical outcomes than surgery/antifungal treatment. The antifungals prescribed were mainly amphotericin B, posaconazole, and amphotericin-posaconazole. Most patients with mucormycosis infection were admitted in the summer. Overall mortality in the identified cases was 30.6%, with the highest mortality rate in patients diagnosed with pulmonary infection.</p><p><strong>Conclusion: </strong>The current study is the largest single-country retrospective study on the topic, with 601 mucormycosis cases. It may uncover gaps in knowledge, develop recommendations for future studies, and clarify the clinical and epidemiological aspects of mucormycosis. However, future studies and clarification of mucormycosis's clinical and epidemiological aspects are highly recommended.</p>","PeriodicalId":19017,"journal":{"name":"Mycopathologia","volume":"190 5","pages":"87"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ten-Year Experience on 601 Patients with Mucormycosis at Eight Tertiary Care Centers in Iran.\",\"authors\":\"Hamid Badali, Bahar Mohamadi, Shahram Mahmoudi, Maryam Nasirian, Siavash Amiri, Shirin Irani, Zeynab Yassin, Narges Vaseghi, Ilad Alavi Darazam, Mohammadreza Salehi, Maryam Roham, Sara Abolghasemi, Farshad Divsalar, Mehrdad Hasibi, Atousa Hakamifard, Maryamosadat Hashemi Bafghi, Simin Saberi, Afsane Vaezi\",\"doi\":\"10.1007/s11046-025-00995-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Mucormycosis is a rare, destructive, and life-threatening angio-invasive fungal infection caused by fungi of the order Mucorales. This study highlights the urgent need for more extensive research in this regard. We aimed to assess the epidemiology of mucormycosis at eight tertiary-care centers in Iran over ten years (2010-2020).</p><p><strong>Methods: </strong>In the current retrospective study, eligible patients were included based on positive histopathology and direct microscopy by potassium hydroxide (KOH). Data collection started on July 26, 2021, and included data from February 15, 2010, to May 16, 2020.</p><p><strong>Results: </strong>Diabetes mellitus was the chief underlying condition related to mucormycosis. Rhino-cerebral, rhino-sino, and rhino-sino-orbital infections were observed in 53.2%, 23.8%, and 23% of these patients. Among the 108 cases with a culture, Rhizopus species were the most prevalent, followed by Mucor species. Over half of the patients received surgery/antifungal treatment, with an overall antifungal prescribing rate of 66.7% of patients within the study period. However, surgery was associated with better clinical outcomes than surgery/antifungal treatment. The antifungals prescribed were mainly amphotericin B, posaconazole, and amphotericin-posaconazole. Most patients with mucormycosis infection were admitted in the summer. Overall mortality in the identified cases was 30.6%, with the highest mortality rate in patients diagnosed with pulmonary infection.</p><p><strong>Conclusion: </strong>The current study is the largest single-country retrospective study on the topic, with 601 mucormycosis cases. It may uncover gaps in knowledge, develop recommendations for future studies, and clarify the clinical and epidemiological aspects of mucormycosis. However, future studies and clarification of mucormycosis's clinical and epidemiological aspects are highly recommended.</p>\",\"PeriodicalId\":19017,\"journal\":{\"name\":\"Mycopathologia\",\"volume\":\"190 5\",\"pages\":\"87\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mycopathologia\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1007/s11046-025-00995-x\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MYCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycopathologia","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11046-025-00995-x","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}
Ten-Year Experience on 601 Patients with Mucormycosis at Eight Tertiary Care Centers in Iran.
Background: Mucormycosis is a rare, destructive, and life-threatening angio-invasive fungal infection caused by fungi of the order Mucorales. This study highlights the urgent need for more extensive research in this regard. We aimed to assess the epidemiology of mucormycosis at eight tertiary-care centers in Iran over ten years (2010-2020).
Methods: In the current retrospective study, eligible patients were included based on positive histopathology and direct microscopy by potassium hydroxide (KOH). Data collection started on July 26, 2021, and included data from February 15, 2010, to May 16, 2020.
Results: Diabetes mellitus was the chief underlying condition related to mucormycosis. Rhino-cerebral, rhino-sino, and rhino-sino-orbital infections were observed in 53.2%, 23.8%, and 23% of these patients. Among the 108 cases with a culture, Rhizopus species were the most prevalent, followed by Mucor species. Over half of the patients received surgery/antifungal treatment, with an overall antifungal prescribing rate of 66.7% of patients within the study period. However, surgery was associated with better clinical outcomes than surgery/antifungal treatment. The antifungals prescribed were mainly amphotericin B, posaconazole, and amphotericin-posaconazole. Most patients with mucormycosis infection were admitted in the summer. Overall mortality in the identified cases was 30.6%, with the highest mortality rate in patients diagnosed with pulmonary infection.
Conclusion: The current study is the largest single-country retrospective study on the topic, with 601 mucormycosis cases. It may uncover gaps in knowledge, develop recommendations for future studies, and clarify the clinical and epidemiological aspects of mucormycosis. However, future studies and clarification of mucormycosis's clinical and epidemiological aspects are highly recommended.
期刊介绍:
Mycopathologia is an official journal of the International Union of Microbiological Societies (IUMS). Mycopathologia was founded in 1938 with the mission to ‘diffuse the understanding of fungal diseases in man and animals among mycologists’. Many of the milestones discoveries in the field of medical mycology have been communicated through the pages of this journal. Mycopathologia covers a diverse, interdisciplinary range of topics that is unique in breadth and depth. The journal publishes peer-reviewed, original articles highlighting important developments concerning medically important fungi and fungal diseases. The journal highlights important developments in fungal systematics and taxonomy, laboratory diagnosis of fungal infections, antifungal drugs, clinical presentation and treatment, and epidemiology of fungal diseases globally. Timely opinion articles, mini-reviews, and other communications are usually invited at the discretion of the editorial board. Unique case reports highlighting unprecedented progress in the diagnosis and treatment of fungal infections, are published in every issue of the journal. MycopathologiaIMAGE is another regular feature for a brief clinical report of potential interest to a mixed audience of physicians and laboratory scientists. MycopathologiaGENOME is designed for the rapid publication of new genomes of human and animal pathogenic fungi using a checklist-based, standardized format.